4.47Open4.47Pre Close0 Volume1 Open Interest12.50Strike Price0.00Turnover0.00%IV-54.72%PremiumMay 16, 2025Expiry Date7.31Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.71Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet